-+ 0.00%
-+ 0.00%
-+ 0.00%

Thermo Fisher Scientific (TMO) Beat Estimates And Launched VaxEvo, Is An 11% Discount Enough?

Simply Wall St·11/21/2026 15:11:43
Listen to the news

Why Thermo Fisher Scientific Stock Is Back in Focus

Thermo Fisher Scientific (TMO) just paired strong third quarter earnings that topped analyst expectations with the launch of its Gibco VaxEvo CD 293 Medium for higher efficiency adenovirus vaccine production.

Thermo Fisher Scientific’s recent catalysts, including the VaxEvo CD 293 launch and a high profile CEO appearance at the UBS 2026 conference on 19 November, come against a mixed backdrop. The share price is down 4.4% over the past week, yet the stock still shows a 13.0% year to date share price return and a 14.4% total shareholder return over the past 12 months. This points to longer term momentum that has eased in the very short term as investors reassess growth potential and risks after a strong run.

Compare Thermo Fisher Scientific’s momentum and vaccine exposure with a hand picked set of 35 healthcare AI stocks that harness data and automation to reshape drug development and diagnostics.

The latest pullback clashes with Thermo Fisher Scientific’s earnings beat and new vaccine medium launch. This week’s weakness may indicate a shift in sentiment or a mismatch between business performance and what investors are willing to pay.

Most Popular Narrative: 11% Undervalued

Thermo Fisher Scientific last closed at $669.54, compared with an analyst consensus fair value of $750.92 in the analyst consensus Narrative on Simply Wall St, which blends Street forecasts for revenue, earnings and margins with an 8.37% discount rate.

Improving funding and higher activity in pharma and biotech, which represent about 60% of Thermo Fisher Scientific revenue and have delivered several quarters of sequentially stronger organic growth, are expected to support continued demand for research reagents, clinical trial services and bioproduction, with a direct effect on revenue growth and operating leverage.

See why 104 investors see Thermo Fisher Scientific as 11% undervalued.

Result: Fair Value of $750.92 (UNDERVALUED)

Still, the narrative can crack if academic and government funding remains sluggish, or if the microbiology sale weighs on earnings more than analysts currently build in.

Find out about the key risks to this Thermo Fisher Scientific narrative.

Another View: What Thermo Fisher Scientific’s P/E Is Telling You

Thermo Fisher Scientific might look appealing against the analyst fair value of $750.92, yet the simple P/E check tells a tougher story. The stock trades on 35.1x earnings, richer than both the Global Life Sciences average at 32.6x and its own fair ratio of 37.3x.

This gap leaves less room for error. If sentiment cools and the market leans closer to sector norms rather than the higher fair ratio, investors could feel that shift quickly in the share price. Is that premium one you are comfortable paying for the current growth profile and risk mix?

See what the numbers say about this price — find out in our valuation breakdown.

NYSE:TMO P/E Ratio as at Nov 2026
NYSE:TMO P/E Ratio as at Nov 2026

Next Steps

Mixed messages on Thermo Fisher Scientific can create noise, yet the fastest way to cut through it is to look at the numbers yourself, weigh the trade off between the risks that concern investors and the rewards they are optimistic about, and then see how that balance shows up in the 1 key reward and 2 important warning signs.

Looking for more Thermo Fisher Scientific style investment ideas?

If Thermo Fisher Scientific has your attention, do not stop here. Broaden your watchlist with fresh opportunities that match different return and risk preferences across the market.